Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00230074 | A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS) | PHASE2 | COMPLETED | 350 | — | — | Nov 1, 2004 | Feb 1, 2005 | Nov 23, 2011 | 1 | United States |
| NCT00072709 | Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | 551 | — | — | Sep 1, 2003 | Dec 1, 2004 | Nov 24, 2011 | 9 | United States, Belgium +7 |
| NCT00036413 | A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | 44 | — | — | Jan 1, 2002 | Oct 1, 2002 | Nov 24, 2011 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| TCH346 | DRUG | - |
Inclusion Criteria: * Completed original protocol, Study No. CTCH346A2211 * Be capable of satisfying the requirements of the extension protocol and must sign informed consent after the nature of the extension protocol has been fully explained Exclusion Criteria: * Exclusion criteria as described ...